News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novadaq Corp. Reports Second Quarter 2014 Financial Results


8/5/2014 8:01:49 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TORONTO, Aug. 5, 2014 (GLOBE NEWSWIRE) -- Novadaq® Technologies Inc. ("NOVADAQ" or the "Company") (Nasdaq:NVDQ) (TSX:NDQ), the leading developer and provider of clinically relevant imaging solutions for use in surgical and diagnostic procedures, today announced financial results for its second quarter ended June 30, 2014. Unless otherwise indicated, all dollar amounts in this press release are expressed in United States ("U.S.") dollars.

NOVADAQ reported second quarter 2014 revenues of $11.2 million, compared to $8.1 million in the second quarter of 2013, representing an increase of 38%. NOVADAQ's strategy of investing in a direct sales team resulted in $5.1 million in PINPOINT® and LUNA® sales compared to $1.2 million in the second quarter of last year. During the second quarter, royalty revenues were recognized only from da Vinci® Si systems, while royalty revenues from the new da Vinci Xi systems are delayed until U.S. Food and Drug Administration clearance is received.

NOVADAQ estimates that procedures performed using SPY® technology systems during the quarter was 7,400, representing an increase of 39%, year-over-year and an increase of 13% over the previous quarter. The increase was mainly driven by PINPOINT, LUNA and FIREFLY™.

Second quarter gross profits of $6.9 million (62% margin), represented an increase of 37% compared to profits of $5.1 million (62% margin) in the same period last year.

Net income of $6.3 million for the second quarter of 2014 increased by $16.0 million compared with the $9.7 million net loss in second quarter of 2013. Second quarter 2014 earnings per share were $0.11, excluding the impact of a non-cash $10.8 million warrants revaluation gain in the period, the loss per share was $0.08.

Second quarter 2014 operating burn (cash consumed by operating activities before changes in working capital) was $1.5 million compared to an operating burn of $0.6 million in the second quarter of 2013. This difference in operating burn was mainly driven by increased sales and distribution expenses associated with the build-out of NOVADAQ's direct sales and marketing infrastructure. During the period, working capital consumed was $5.7 million, and $1.8 million was invested in fixed assets, including $1.7 million used to build SPY technology systems for evaluation and placement. The Company also utilized $6.7 million in cash, inclusive of transaction costs, to complete the acquisition of Aïmago SA business.

Cash and cash equivalents were $162.1 million at June 30, 2014, reflecting a decrease of $15.1 million, compared to the cash position as at March 31, 2014.

During the second quarter, 129 SPY technology systems, including FIREFLY, were shipped globally. Included in those shipments were sales of 47 PINPOINT, LUNA and SPY systems. Exiting the quarter, more than 100 PINPOINT and LUNA systems were installed as evaluation units.

"The second quarter marks a milestone for us, as approximately half of our revenues were generated from direct sales," commented Dr. Arun Menawat, NOVADAQ President and CEO. "In line with the clinical value proposition of our products, we are announcing the initiation of two multi-center studies using PINPOINT: PILLARTM III, focused on lower anterior colon resection and the FILMTM study for lymphatic mapping in gynecological oncology."

Conference Call Details

NOVADAQ is pleased to invite all interested parties to participate in a conference call, on August 5, 2014 at 8:30 a.m. Eastern Time, during which the results will be discussed.

Those wishing to access the live conference call by telephone should dial 1-877-407-8031 (Canada and the United States) or 1-201-689-8031 (International) several minutes prior to the beginning of the call.

A replay of the conference call can be accessed by dialing 1-877-660-6853 (Canada and the United States) or 1-201-612-7415 (International) and entering the conference identification number 13587138 when prompted.

The call will also be archived for 90 days on the Company's website at novadaq.com under the "Events" tab in the Investor's section. A replay of the call will be available for download to a portable audio player or computer, as an MP3 or podcast file, at the same location on NOVADAQ's website.

About Novadaq Technologies Inc.

Enabling medical professionals with clinically relevant, point-of-care imaging solutions to enhance the lives of patients and their caregivers, while reducing health care costs, is NOVADAQ®'s global mission. SPY® fluorescence imaging technology provides surgeons with real-time visualization, leading to improved outcomes and reduced costs without exposing the patient to radiation. More than 100 peer-reviewed publications demonstrate that the use of SPY imaging technologies during complex surgery and diagnostic procedures, leads to lower rates of post-operative complications and lower hospital costs.

SPY Imaging Systems are United States Food and Drug Administration 510(k) cleared for use in seven surgical specialties. The endoscopic version of SPY called PINPOINT®, combines the capabilities of SPY Imaging with high definition ("HD") visible light visualization offered by conventional endoscopes. LUNA® is used to assess perfusion in patients being treated for non-healing wounds.

Forward Looking Statements

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on NOVADAQ's current beliefs as well as assumptions made by and information currently available to NOVADAQ and relate to, among other things, the Company's strategy, strategic goals, research and development activities, research and clinical testing outcomes, taxes, capital expenditures, future operations, future financial position, future revenues/results, projected costs, prospects and plans and objectives of management.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by NOVADAQ in its public securities filings available at www.sec.gov and www.sedar.com, actual events may differ materially from current expectations. NOVADAQ disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For full article, please click here.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES